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The prevalence of obesity has increased substantially in the recent decades, along with 
associated co-morbidities such as insulin resistance, type 2 diabetes mellitus (T2DM) and 
cardiovascular diseases (CVDs). Moreover, obesity is associated with a state of chronic low-
grade inflammation which is thought to be one of the main driving forces for the 
development of insulin resistance and T2DM. However, the causal relationship is still 
controversial. The inflammation in adipose tissue has been characterized by the secretion of 
pro-inflammatory cytokines and infiltration of pro-inflammatory macrophages. In particular, 
an increased tendency of accumulating fat in the visceral adipose tissue have been 
associated with adipose tissue inflammation and an increased risk of associated co-
morbidities. 
In this project, we aimed to quantify the level of macrophage infiltration into subcutaneous 
(SAT) and visceral adipose tissue (VAT) of severely obese subjects undergoing bariatric 
surgery. Furthermore, we phenotypically characterized pro-inflammatory M1-like 
macrophages (CD11c+CD206+) and anti-inflammatory M2-like macrophages (CD11c-
CD206+) by the expression of known pro-inflammatory receptors and investigated whether 
the level of pro- and anti-inflammatory macrophages associated with insulin resistance and 
other clinical parameters relevant for metabolic syndrome. We also analyzed the expression 
level of pro- and anti-inflammatory genes and performed functional analysis on isolated 
mature adipocytes from SAT and VAT, focusing on differences between the two depots.  
We found that macrophages are more abundant in SAT than in VAT. Moreover, insulin 
resistance (HOMA-IR) was associated with a higher ratio of the anti-inflammatory M2/M1-
like macrophages and a higher expression of the anti-inflammatory receptors CD163 and 
TREM2 in SAT. We also found that systemic inflammation was associated with a higher ratio 
of pro-inflammatory M1/M2-like macrophages and a pro-inflammatory gene expression 
pattern in VAT. Moreover, the chemotactic receptor, CCR2, was found to be highly 
expressed by M1-like macrophages and almost absent from M2-like macrophages. Further, 
we found that lipolysis was significantly higher in VAT compared to SAT of obese subjects, 







Obesity is a complex disease and a major public health concern because of its increasing 
prevalence worldwide. Obesity results from excessive caloric intake over time. Excessive 
calories in the form of carbohydrate, fat and proteins are converted into triglycerides which 
are stored in adipose tissue leading to expanding adipose tissue (Burhans, Hagman et al. 
2018).  A common method to quantify the level of obesity have been the BMI (body-mass 
index) scale, where the weight in kilograms is divided by the square of the height in meters 
(Chooi, Ding et al. 2019). A BMI of 20-25 defines the normal healthy level, 25-29 as 
overweight and above 30 as obesity, while above 40 is considered morbidly obese. However, 
using the BMI designation to quantify obesity is limited by the fact that it cannot distinguish 
between fat and muscle mass and is not diagnostic of the body fatness, health status and 
associated risks. Furthermore, BMI do not differentiate between different fat depots (Chooi, 
Ding et al. 2019).  
Obesity is associated with elevated risk of several severe implications, such as metabolic 
syndrome, insulin resistance and T2D, atherosclerosis and an elevated risk of several forms 
of cancer which has brought a lot of attention in research on the pathogenesis of obesity 




The prevalence of obesity has increased substantially in the last four decades and, nearly a 
third of the world population is now classified as overweight or obese. If the current trend 
continues it is estimated that more than half of the world population will be overweight or 
obese by 2030 (Chooi, Ding et al. 2019). Obesity is considered a major risk factor for 
developing insulin resistance and T2DM. Studies show that about 80% of the individuals 
diagnosed with T2DM are obese (Kennedy, Martinez et al. 2009). Besides increasing the risk 
of several serious diseases, obesity has a major socioeconomic cost by impacting on quality 
of life, work productivity and health costs. The cause of the obesity epidemic has been 
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attributed to the modern western diet consisting of more processed, energy dense, nutrient 
poor and affordable food and beverages which facilitates overconsumption. A major 
contribution also comes from a coincidence of decreased physical activity in the population 
owing to modernization of lifestyles (Chooi, Ding et al. 2019). In high income countries, 
obesity is most prevalent among poor and disadvantaged groups at all ages, while in low 
income countries obesity mostly affect middle-aged people from wealthy and urban 
environments. Also, the prevalence of obesity is generally higher in women than men at all 
sociodemographic levels (Chooi, Ding et al. 2019). During the last decade or so it has been 
observed that the increase in obesity rates have levelled off to some extent in many of the 
high-income countries. On the other hand, the obesity rates have accelerated in other parts 
of the world, especially in developing countries. This is most likely a result of rapid change in 
socioeconomic status, and adaption of a western diet accompanied by a more sedentary 
lifestyle, but globally the rate is still increasing (Chooi, Ding et al. 2019). It is debated 
whether the obesity epidemic may be slowing down in Norway as well. But a large study in 
the adult population in Norway (n = 90000) found that from the period 1984-1986 through 
1995-1997 to 2006-2008 the mean BMI increased from 25.3 to 26.5 and 27.5 kg/m2 in men 
and from 25.1 to 26.2 and 26.9 kg/m2 in women respectively. While the increase in 
prevalence of obesity (BMI >30 kg/m2) raised from 7.7 to 14.4 and 22.1% for men and from 
13.3 to 18.3 and 23.1% in women during the same period and found no signs of reduction in 
incidence of obesity during the follow-up period (Midthjell, Lee et al. 2013). Concomitant 
with the increase in obesity there have been a rapidly increase in incidence and prevalence 
of T2DM. A large metanalysis of 751 studies including 4 372 000 adults from 146 countries 
found that the global prevalence increased from 4.3% in 1980 and up to 9% in 2014 for men 
and from 5.0% up to 7.9% for women (Collaboration 2016). The number of total diabetes 
cases raised from 108 million up to 422 million during the same period. Lowest prevalence 
was observed in northwestern Europe and highest prevalence was observed in Polynesia and 
Micronesia (Collaboration 2016). In Norway, the incidence rate has been reported to level 
off to some degree in recent years. From 2009 to 2014 it was reported that the incidence 
decreased from 609 cases per 100 000 persons a year down to 398 cases per 100 000 
persons a year in 2014. Meanwhile the prevalence is still increasing, up from 4.9% to 6.1% 
during the same period, and is probably explained by diagnosis at a younger age and 
increased longevity (Ruiz, Stene et al. 2018). 
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1.3 Insulin resistance and Type II diabetes 
 
Because of the increasing prevalence of T2DM worldwide, it has been put down a lot of 
effort to understand the mechanisms of insulin resistance and β-cell dysfunction which are 
the leading cause of T2DM (Kahn, Cooper et al. 2014). In the normal healthy state, glucose 
metabolism is regulated by a feedback loop involving the insulin secreting islet β-cell of the 
pancreas and insulin sensitive tissue such as liver, muscle, and adipose tissue (Kahn, Cooper 
et al. 2014). Insulin is secreted in response to elevated blood glucose levels in the 
postprandial phase and acts by suppressing glucose production in the liver and stimulates 
uptake of glucose in liver, muscle and adipose tissue by promoting translocation of GLUT4 to 
the plasma membrane (Kahn, Cooper et al. 2014). Most of insulin action is mediated by AKT 
which is activated in a signaling cascade downstream of the insulin receptor (Figure 1.1.A). 
AKT also stimulates anabolic processes such as glycogenesis, de novo lipogenesis and protein 
synthesis, while at the same time inhibiting the opposing pathways (Huang, Liu et al. 2018). 
Perturbation of components in the insulin signaling cascade is a characteristic of insulin 
resistance and consequently lack of AKT stimulation diminishes GLUT4 translocation to the 
membrane leading to elevated blood glucose levels, which is magnified by the lack of 
inhibition of gluconeogenesis in liver (Figure 1.1. B). Lack of AKT signaling also diminishes the 
inhibitory effect on lipolysis, increasing the levels of circulating free fatty acids (FFA) which is 
taken up by muscles, liver and pancreas or deposited on ectopic places, contributing to 
lipotoxicity (Huang, Liu et al. 2018). It has been found that FFA and other metabolites that 
are increased during insulin resistance such as diacylglycerol (DAG), ceramides and acyl-CoA, 
could stimulate several protein kinases such as IKK-β, JNK and several isoforms of PKC to 
phosphorylate IRS-1 (Figure 1.1.B) attenuating the insulin signaling pathway (Szymczak-Pajor 





Figure 1.1 The insulin signaling pathway during normal physiological conditions (A) and insulin resistance (B). Insulin 
binding to its receptor is followed by dimerization and autophosphorylation of tyrosine residues on the cytosolic part of the 
receptor. Phosphotyrosine functions as docking sites for insulin-receptor substrate proteins which gets phosphorylated by 
the receptor and promote activation and translocation of PI3K to the membrane were PI3K phosphorylates PIP2 to PIP3. 
Elevation of PIP3 promotes activation of serine threonine kinase PDK1, which phosphorylates PKC and AKT leading to their 
activation. AKT and PKC mediates translocation of glucose transporters GLUT4 to the plasma membrane to elevate glucose 
uptake.  AKT also promote glycogenesis, lipogenesis and protein synthesis. During insulin resistance (B), the insulin signaling 
pathway is attenuated by inhibitory phosphorylation of IRS1 by several kinases such as IKK-β, JNK, and different isoforms of 
PKC. Failure of translocating GLUT4 to the plasma membrane leads to elevated blood glucose, in addition AKT will not 
mediates its other actions in response to insulin such as inhibiting lipolysis and gluconeogenesis in adipose tissue and liver, 





 The amount of insulin secreted from the β-cells are dependent upon the sensitivity of the 
target tissue, and when insulin resistance develops the β-cells try to cope with that by 
increasing insulin secretion to maintain glucose homoeostasis. Impaired glucose tolerance 
recognized by prolonged elevated glucose levels after a meal arise when the β-cells are 
incapable of increasing insulin secretion to cope with the worsening insulin resistance 
eventually leading to β-cell dysfunction (Kahn, Cooper et al. 2014). T2DM is a heterogeneous 
disease characterized by β-cell dysfunction in the pancreas, affecting insulin secretion and 
the insulin sensitivity in target tissues. The causes include both genetic and environmental 
contributions (Kahn, Cooper et al. 2014). Obese individuals are found to have a higher risk of 
developing T2DM suggesting that adipose tissue is likely to play a role in the pathogenesis of 
the disease (Scheen 2003). The level of insulin resistance has commonly been quantified by 
the HOMA-IR scale, which is calculated on the fasting levels of glucose and insulin (equation 
1.1) (Kim, Seol et al. 2019). 
(1.1) 
𝐻𝑂𝑀𝐴 − 𝐼𝑅 =  
𝐺𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑛𝑚𝑜𝑙







1.4 Adipocytes and adipose tissue 
 
Adipose tissue serves several important physiological functions in our body and is commonly 
divided into two subtypes, white adipose tissue (WAT) and brown adipose tissue (BAT) 
(Saely, Geiger et al. 2012). WAT is most abundant and could broadly be divided into 
subcutaneous adipose tissue (SAT) which is located underneath the skin, and the visceral 
adipose tissue which surrounds the internal organs. The main role of WAT is to store excess 
calories consumed in the form of triglycerides, which can be used later for energy 
(Murawska-Cialowicz 2017). WAT also serves an important function as an endocrine organ, 
secreting adipokines, such as leptin, adiponectin and omentin which have important 
regulatory functions on fatty-acid oxidation, lipogenesis, gluconeogenesis, glucose uptake 
and insulin signaling in metabolically important tissues such as skeletal muscle, liver and 
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brain (Chait and den Hartigh 2020). BAT serves a function in heat production by metabolizing 
fatty acids and dissipates the energy as heat through mitochondrial uncoupling. BAT is most 
abundant in newborns and in particular small mammals enabling them to thrive in cold 
environments. The extent of BAT in adults and its physiological relevance is still not fully 
elucidated (Saely, Geiger et al. 2012). WAT is composed mostly of adipocytes, loose 
connective tissue and the stromal vascular fraction (SVF), which includes fibroblasts, 
preadipocytes, vascular endothelial cells and immune cells such as macrophages, NK-cells, T- 
and B-lymphocytes (Martyniak and Masternak 2017). WAT exhibits a tremendous capacity of 
expansion, mostly through the process of cell growth known as hypertrophy, but also 
through division of stem cells and differentiation of pre-adipocytes, a process known as 
hyperplasia (Zhang, Xie et al. 2017). Several studies have shown that there are great inter-
individual differences in the capacities of hypertrophy and hyperplasia, which could have 
implications for disease risk (Zhang, Xie et al. 2017). 
 
1.5 Adipose tissue depots and metabolically healthy obesity 
Some obese individuals appear to be better protected against metabolic abnormalities and 
has been referred to as metabolic healthy obese (MHO) (Iacobini, Pugliese et al. 2019). It is 
widely accepted among researchers in the field that central body fat distribution and 
impaired adipose tissue function are better predictors of obesity-associated metabolic 
syndrome than total fat mass and BMI (Iacobini, Pugliese et al. 2019). To eliminate subjective 
bias, it has been suggested that six parameters should be considered in classifying metabolic 
syndrome: waist circumference, insulin resistance, blood sugar levels, blood pressure, 
cholesterol levels and physical fitness. Which parameters best defining MHO has not been 
established yet, but most researchers agree on reduced accumulation of visceral adipose 
tissue (VAT) and ectopic fat, preserved insulin sensitivity and a lower degree of systemic and 
adipose tissue inflammation to be some of the defining features of MHO (Iacobini, Pugliese 
et al. 2019).  
Several factors regulate fat distribution in various adipose tissue depots. Age, sex and total 
body fat content are the main predictors of body fat distribution, but evidence indicates that 
genetic factors also have a major impact on fat distribution at any given BMI. Several studies 
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have attested the waist to hip ratio, a measure of fat distribution and found it to be highly 
heritable with estimates of up to 60% (Goodarzi 2018). SHOX2 is an example of a gene 
pointed out as a major determinant of regional fat distribution. SHOX2 expression in 
subcutaneous adipose tissue (SAT) correlates positively with both lipolysis activity of SAT 
adipocytes and visceral adiposity (2016). Also, there is evidence that developmental genes 
are differentially expressed in various fat depots and might play a role in the regulation of fat 
distribution and thereby also obesity-related metabolic traits (2016). This suggest that the 
difference between the MHO and metabolically unhealthy obese (MUO) phenotype is partly 
caused by genetic traits modulating body fat distribution between the different fat depots, 
which hold diverse biological properties and functions. Evidence indicates that not all fat 
depots are equally hazardous for health. Stronger associations are found between VAT and 
ectopic fat accumulation around liver, heart and muscles, with insulin resistance and CVD 
(Lebovitz and Banerji 2005). The type of fat also matters, WAT is strongly associated with 
obesity related metabolic disorders. BAT, on the other hand has a large potential of fat 
burning and confers a protective role for metabolic and cardiovascular health, although its 
contribution on whole body glucose homeostasis is still questionable (Chondronikola, Volpi 
et al. 2014).  
MHO subjects are characterized by a greater tendency of storing fat in the SAT depot and 
less in VAT, and ectopic sites compared to MUO at the same BMI and fat mass. A greater 
tendency of fat accumulation in the lower part of the body compared to abdominal fat 
accumulation is also a determinant of MHO (Iacobini, Pugliese et al. 2019). Therefore, the 
reason why MHO are better protected against obesity related disorders could in part be 
explained by the divergent regulatory functions of VAT and SAT, contributing to a greater 
capacity of SAT expansion to buffer against lipid overflow, and thereby reducing fat 
deposition in abdominal VAT and at ectopic sites such as muscle, pancreas and liver 
(Iacobini, Pugliese et al. 2019). In summary, the metabolic health of an individual is likely to 
depend on the adipogenic capacity of adipose tissue, which favor lipid buffering. For each 
individual there is a threshold for the adipogenic capacity, and once this threshold is 
exceeded, lipids get deposited on ectopic sites leading to metabolic abnormalities (Iacobini, 
Pugliese et al. 2019).  This hypothesis of a personal fat threshold could also explain the 
existence of metabolic unhealthy lean individuals. In addition, studies have found that 
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lifestyle habits might partly explain the heterogeneity of obesity in terms of metabolic 
abnormalities. In line with that, MHO phenotype is more frequently observed in younger and 
female adults, and in addition, the MHO is more likely to exercise and less likely to smoke or 
drink heavily (Iacobini, Pugliese et al. 2019). 
 
1.6 Adipocyte cell size and insulin resistance 
 
In order to maximize the amount of energy stored by each adipocyte, these cells are forming 
a large lipid droplet comprising almost the entire volume of the cell, only separated from the 
plasma membrane by a thin rim of cytoplasm (Zhang, Xie et al. 2017). During obesity the 
adipocytes increase their volume tremendously, and studies have found that adipocyte size 
has been correlated with obesity associated diseases such as T2DM and insulin resistance 
(Zhang, Xie et al. 2017). In line with this finding, obese subjects with a greater quantity of 
smaller adipocytes, indicative of a greater tendency of hyperplastic growth seems to be 
better protected against obesity related diseases (Zhang, Xie et al. 2017). In support to this, 
GWAS has found associations of genes involved in regulation of adipocyte development such 
as PPAR-γ with insulin resistance, and failure of adipocyte development as occurs in some 
lipodystrophy diseases causes severe systemic insulin resistance (Petersen and Shulman 
2018). The orphan nuclear receptor NR4A1, also known as NUR77 is an important 
component in the regulatory control of adipocyte quiescence, and its expression is found to 
have a negative influence on the metabolically beneficial adipose tissue plasticity (Zhang, 
Federation et al. 2018). NR4A1 could thus be a major contributor to the tendency of mature 
adipose tissue to expand primarily through hypertrophic rather than hyperplastic growth 
and may account for some of the inter individual variability. It has been hypothesized that 
obesity represent a state with relative resemblance to lipodystrophy, and that T2DM arise 
when the adipocyte hypertrophic and hyperplastic capacity is insufficient to accommodate 
the metabolic stress of chronic caloric excess, leading to an increasing tendency towards 
lipids being deposited on ectopic places such as the liver, pancreas and muscle (Zhang, 





1.7 Ectopic fat deposition, adipocyte lipolysis and insulin resistance 
 
Adipocytes serve important functions during period of energy demand such as fasting or 
physical exercise by mobilizing fatty acids to serve as energy in tissues such as muscle, and to 
provide fatty acids and glycerol to the liver for synthesis of ketone bodies, and to serve as 
precursor for production of glucose in the process of gluconeogenesis respectively (Lass, 
Zimmermann et al. 2011). During lipolysis, triacylglycerols are hydrolyzed into fatty acids and 
glycerol by the sequential action of the three major lipases adipose triglyceride lipase 
(ATGL), hormone sensitive lipase (HSL) and monoacylglycerol lipase (MAGL). FFA and glycerol 
are released into the circulation and transported to tissues such as muscle and liver (Lass, 
Zimmermann et al. 2011).  
Lipolysis is carefully regulated by the actions of catecholamines, natriuretic peptides and 
insulin. Catecholamines and natriuretic peptides are considered the main stimulators of 
lipolysis, although some catecholamines are inhibitory, while insulin is considered the main 
hormone for inhibition of lipolysis (Lass, Zimmermann et al. 2011). Studies have found that 
the lipolytic response of catecholamines is reduced in SAT but increased in VAT of obese and 
insulin resistant subjects (Lass, Zimmermann et al. 2011). Moreover, it is reported that the 
basal rate of lipolysis is increased in the obese state, which could be a consequence of the 
tremendous volumetric expansion of adipocytes in obesity to the point were further 
expansion is not feasible. It is hypothesized that the increased rate of basal lipolysis worsens 
the lipid accumulation on ectopic sites such as liver, pancreas and muscle, leading to 
impaired insulin sensitivity in those tissues (Lass, Zimmermann et al. 2011). In addition, 
higher rates of lipolysis may modulate the secretory profile of adipocytes to release 
adipokines and promote adipose tissue inflammation by stimulate resident adipose tissue 
macrophages (ATM) to production of cytokines and chemokines, attracting additional 
macrophages. Numerous studies have pointed on the association between ectopic lipid 
accumulation and insulin resistance. Ceramides and DAG is pointed out as the suspected 
molecular species impairing insulin signaling, and studies has shown that lipid infusion in 
healthy lean people transiently increase cytosolic DAG content and promote insulin 
resistance (Morigny, Houssier et al. 2016). Moreover, studies in rats has shown that DAG is 
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able to activate PKCε which directly interfere with the insulin signaling pathway by 
phosphorylating components in the pathway such as IRS1 and RPS6 (Gassaway, Petersen et 
al. 2018).  It is also believed that the increase in circulating FFA and glycerol exacerbate 
hyperglycemia by serving as precursors and also stimulate gluconeogenesis (Morigny, 
Houssier et al. 2016). In addition, elevated FFA can acts as ligands for TLR4 receptors on 
macrophages, activating the NF-κB pathway leading to cytokine release (Kim, Seol et al. 
2019).  
 
1.8 Adipose tissue as an endocrine organ 
 
Although adipose tissue traditionally has been recognized for its function in energy storage 
the latest decades of research have firmly elucidated its endocrine function. Already in 1987 
it was discovered that adipose tissue has an important function in metabolism of sex 
hormones, and in 1994 followed the discovery of leptin, a hormone which have shown to 
play a major role in obesity (Mark 2013). It is now well established that adipose tissue 
secretes a wide variety of autocrine, paracrine and endocrine peptide hormones known as 
adipokines (Kershaw and Flier 2004). It is also found that adipose tissue expresses an array 
of receptors that enables the tissue to respond to signals from endocrine organs elsewhere 
in the body and the central nervous system. Through this network it is shown that adipose 
tissue is an important contributor in coordinating processes such as energy metabolism, 
neuroendocrine function and immune function (Kershaw and Flier 2004). 
Leptin has been discovered as an adipokine with a central role in energy homeostasis which 
is mediated through hypothalamic signaling. Secreted leptin signals energy sufficiency by 
inducing sensation of satiety and contribute to reduced food intake and increased energy 
expenditure (Kershaw and Flier 2004). Leptin knock-out mice present with severe obesity 
which is shown to be reversed by leptin replacement. Nevertheless, many obese experience 
elevated levels of leptin and is resistant to the action of leptin, and thus cannot be treated 
by supplementing exogenous leptin (Kershaw and Flier 2004).  
Adiponectin is another adipokine that is highly expressed and secreted by adipose tissue and 
accounts for 0.01% of total serum levels. Its expression is found to have a beneficial effect on 
insulin sensitivity, atherosclerosis and inflammation, and moreover, decreased expression of 
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adiponectin is closely associated with obesity (Chen, Montagnani et al. 2003). It is discovered 
that adiponectin has key roles in energy metabolism in several metabolically important 
tissues. Adiponectin is shown to activate AMPK, mediated through binding AdipoR1 receptor 
leading to increased insulin sensitivity and glucose uptake in adipose tissue, muscle and liver. 
In addition, adiponectin also inhibits gluconeogenesis in the liver by activating AMPK (Yilmaz, 
Biyikoglu et al. 2003), (Nawrocki, Rajala et al. 2006). Other actions of adiponectin are 
mediated through AdipoR2 receptors which activate the PPAR-α pathway leading to 
increased fatty acid oxidation and reduce inflammation (Kubota, Terauchi et al. 2002). The 
anti-inflammatory activity of adiponectin has implications for several inflammatory diseases 
including insulin resistance, atherosclerosis and cardiovascular diseases (CVDs). In vitro 
studies have shown that the anti-inflammatory actions of adiponectin are mainly driven by 
activation of AMPK and cAMP-PKA in macrophages, endothelial, epithelial and muscle cells, 
which stimulate the expression of anti-inflammatory IL-10. Moreover, in macrophages 
adiponectin also attenuates expression of the pro-inflammatory cytokines TNF and IL6 
through inhibitory actions on the pro-inflammatory NF-kB pathway (Ouchi and Walsh 2007).  
 
 
1.9 Adipose tissue as an immune organ and its implications for disease 
 
Besides its roles in fat storage and endocrine functions, adipose tissue has also been 
recognized as an immune organ (Stolarczyk 2017). Adipose tissue hosts a vast array of 
immune cells such as macrophages, NK-cell, T- and B-lymphocytes. Research have 
discovered that composition of different immune cell populations is modulated in the setting 
of obesity, and obesity is now recognized as a low-grade chronic inflammatory disease 
(Stolarczyk 2017). In lean individuals, adipose tissue secretes anti-inflammatory adipokines 
such as IL-10 and resident immune cells exhibit an anti-inflammatory phenotype (Pahlavani, 
Ramalho et al. 2017). In obesity, it has been reported that secretion of IL-1β, TNF, IFN-γ and 
MCP-1 by adipocytes and resident immune cells attracts additional immune cells such as 
macrophages, NK-cells, T- and B-cells into the tissue and exacerbate the inflammation. 
(Stolarczyk 2017). Moreover, the proinflammatory cytokines TNF and IL6 have been shown 
to suppress the insulin signaling in adipocytes suggesting a causal link between inflammation 
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and insulin resistance (Stolarczyk 2017). The most prominent of the infiltrating immune cells 
are the macrophages which is found to account for 30-50% of the non-adipocyte cell fraction 
in adipose tissue (Boutens and Stienstra 2016). Although obesity is associated with a state of 
chronic low-grade adipose tissue inflammation, the immune cells that infiltrates adipose 
tissue during obesity also perform important homeostatic functions such as breaking down 
extracellular matrix (ECM) proteins to permit healthy expansion of adipose tissue by creating 
room for new adipocytes, followed by creation of new ECM, a process known as tissue 
remodeling. This process is mainly driven by macrophages which also stimulate 
angiogenesis, the development of new blood vessels to provide oxygen and nutrients to the 
expanding adipose tissue (Burhans, Hagman et al. 2018). Macrophages are also able to take 
up FFA that expanded adipocytes are unable to store. It has been discovered that 
macrophages gather around dying adipocytes, making up an aggregate which is described as 
crown-like structures, where macrophages contribute to clearance of lipids and removal of 
cellular debris. Through these mechanisms macrophages thereby provide an additional layer 
of lipid buffering capacity (Cinti, Mitchell et al. 2005).   
More recent research has led to the hypothesis that adipose tissue in obesity transform from 
healthy expanding tissue into becoming inflamed when the ability of the tissue to induce 
adipogenesis and differentiate new adipocytes becomes limited. The continued exposure to 
excess nutrients leads to a stress response in enlarged adipocytes, causing them to express 
and secrete pro-inflammatory adipokines such as TNF-α, MCP-1 and IL6 which results in 
infiltration of bone-marrow derived monocytes and a polarization of macrophages into a 
pro-inflammatory state (Burhans, Hagman et al. 2018). It is proposed that the adipose tissue 
inflammation is part of a protective mechanism, by inducing insulin resistance to prevent cell 
death, and to provide additional lipid buffering capacity from the macrophages. During 
short-term caloric excess, low-level inflammation and adipose tissue macrophage (ATM) 
activation could be beneficial in the sense of providing enough time for the adipose tissue to 
expand. But in situations of chronic caloric excess, the non-resolving inflammation could be 
detrimental, and the continued insulin resistance would lead to elevated lipolysis, 
overwhelming the lipid buffering capacity of macrophages and contribute to ectopic lipid 
storage (Burhans, Hagman et al. 2018).  
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Traditionally, two populations of ATMs have been described. In lean individuals they mostly 
confine to an alternative activated M2-like phenotype characterized by increased expression 
of IL10 and arginase and has mostly been associated with homeostatic functions such as 
facilitating adipogenesis. Another ATM population which is increased in obesity shows 
characteristic of the classical activated M1 macrophages and are distinguished by their high 
expression of the integrin CD11c, and other markers of classical M1-macrophages such as IL6 
and nitric oxide synthase (Wentworth, Naselli et al. 2010). The macrophages are highly 
plastic cells and are likely to respond and adapt to their environment, and a phenotypic 
switch from the M2-like macrophages towards a pro-inflammatory M1-like phenotype has 
been associated with insulin resistance. Moreover, studies in obese mice have shown that 
ablation of CD11c+ cells improves insulin sensitivity (Patsouris, Li et al. 2008).      
Immunohistochemistry and flow cytometry have been the most commonly used methods to 
quantify ATMs, usually by antibodies against the surface receptors CD68, CD14 CD206 or 
CD11c (Morgan-Bathke, Harteneck et al. 2017). However, the two methods show poor 
correspondence, and the fact that there is no unifying concept on how to best characterize 
macrophages and other immune cells possess a challenge when comparing results from 
different studies in this field of research. Immunohistochemistry has good intra-individual 
reproducibility and the advantage of being able to quantify ATMs from preserved whole 
tissue samples but requires high amount of tissue and is time consuming. However, 
improvements in software assisted immunohistochemistry quantification has refined the 
procedure (Morgan-Bathke, Harteneck et al. 2017). Flow cytometry requires less tissue and 
can count millions of cells in a few minutes. In addition, flow cytometry permits the 
simultaneous use of multiple antibodies, providing additional cellular information in one 
experiment. However, this can be complicated by the extensive macrophage 
autofluorescence (Fay, Carll-White et al. 2018). Another big obstacle by using flow cytometry 
is that the individual cell populations within the adipose tissue have to be effectively 
isolated, intact while preserving cellular function (Hagman, Kuzma et al. 2012). The cell 
populations are usually liberated from the tissue by the use of one of two different 
enzymatic preparations; either collagenase alone or a combination of collagenase, liberases 
and other proteases (Hagman, Kuzma et al. 2012). It is reported that there are marked 
differences in cell yields, viability and surface antigen expression between the two methods, 
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which makes it difficult to compare results across studies (Pilgaard, Lund et al. 2008). Studies 
comparing the different methods have reported the use of collagenase alone as superior to 
the use of liberase or liberase collagenase mixtures with respect to cell yield and 
preservation of cell surface receptors, with an optimal digestion time of 60-75 minutes 




1.10 Aim of this study  
 
The introduction is aimed to give an overview of how the physiological aberrations caused 
by obesity can lead to inflammation in the adipose tissue and how this could be linked to 
development of insulin resistance and T2DM. Our hypothesis is that inflammation arise 
when the hyperplastic and hypertrophic capacity of adipose tissue is insufficient to 
accommodate to lipid burden caused by chronic caloric excess leading to increased lipolysis, 
ectopic lipid storage, inflammation and insulin resistance.  
The main questions we want to assess in this study are: 
- Does the macrophages polarization correlate with severity of obesity and insulin 
resistance?   
- Could the alleged pro-inflammatory M1-like macrophages be characterized by the 
expression of other know pro-inflammatory receptors? 
- Is the expression level of proinflammatory cytokines in adipose tissue correlated with 
insulin resistance or circulating markers of inflammation?  
- What is the relative difference between the adipose tissue depots with respect to 
inflammation and insulin resistance? 
- How is lipolysis and glucose uptake in isolated adipocytes associated with systemic 








2.1 Antibodies  




































































2.2 Biological samples 
Tissue Group Source 
Human blood and adipose tissue  
Human Blood and adipose tissue 






2.3 Reagents and chemicals 
Name Supplier Cat.no 
Collagenase type 1 Life Technologies 171000017 
Formaldehyde (2% v/v in PBS) Sigma  P6148 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit Invitrogen L349665 
Lymphoprep Stemcell Techonologies 7851 
Glucose, D-[14C(U)] Perkin Elmer NEC042X050UC 
Insulin (Actrapid 100 IU/mL) Novo Nordisk  
Isoprenaline (247.72 g/mol) Sigma I5627-5g 
Ultima Gold MV Perkin Elmer 6013159 











Buffered saline (D-PBS, 
Sigma #D5652) 
Fluorescence activated 
cell sorting buffer (FACS) 
• 136 mM NaCl 
• 20 mM HEPES 
• 5 mM KCI 
• 5 mM MgSO4 
• 5 mM NaH2PO4 
• 1 mM CaCl2 
• pH 7.4 
• 120 mM NaCl 
• 30 mM HEPES 
• 10 mM NaHCO3 
• 4 mM KH2PO4 
• 1 mM MgSO4 
• 1 mM CaCl2 
• 200 nM 
Adenosine 
• 1 % BSA (w/v) 
• pH 7.4 
• 8 g/L NaCl 
• 1.15 g/L 
Na2HPO4 
• 0.2 g/L KH2PO4 
• 0.2 g/L KCI 
• pH 7.4 
• D-PBS (Sigma 
• #D5652) 
• 2 % (v/v) fetal 
bovine serum 
(FBS) 




2.5 Commercial kits 
Name  Supplier Cat.no 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 4368814 
Free Glycerol Reagent 
LightCycler 480 SYBR Green I Master 
RNA/Protein/DNA purification PLUS kit 
Sigma-Aldrich 
Roche 













2.6 qPCR primers 



































Axiocam ERc 5s 
Centrifuge 5810  
GeneAmp PCR System 9700 
Heraeus Fresco 21 Centrifuge 
Inkubator 1000 
Light Cycler 480 Real-Time PCR 
LSR Fortessa  
Tri-Carb 4910 TR Liquid Scintillation Analyzer 













Name Supplier Identifier 
FlowJo 10 Tree Star https://www.flowjo.com 









To address the aims of this study, we characterized ATMs by flow cytometry, performed 
gene expression analysis in adipose tissue (AT), and measured glucose uptake and lipolysis in 
isolated mature adipocytes from SAT and VAT. The workflow in this study is illustrated in 
Figure 3.1.  
 
 
Figure 3.1: Flowchart depicting the main steps of this project. The project is divided in three main branches: gene 
expression analysis by qPCR, characterization of ATM by flow cytometry and glucose and lipolysis assay. Each branch 





The study includes subjects from three different cohorts. The first cohort of subjects includes 
57 morbidly obese patients undergoing bariatric surgery at Voss Hospital. SAT and VAT 
biopsies from this cohort was used for gene expression analysis. The second cohort was 
included in the flow cytometry analysis and comprise blood, SAT and VAT from 25 patients, 
21 of which were morbidly obese and underwent bariatric surgery and 4 lean controls who 
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underwent cholecystectomy. The last cohort consists of SAT and VAT from 22 morbidly 
obese bariatric surgery patients at Voss hospital and was included in the glucose uptake and 
lipolysis experiments.  
 
Gene expression analysis 
3.2 Isolation of RNA 
 
The adipose tissue was stored at -80°C freezer immediately after surgery and until usage. 
Total RNA was isolated from approximately 100 mg adipose tissue from the subcutaneous 
and visceral depot using the RNA/Protein/DNA purification kit. This work was done by a 
technician in our group.  
 
3.3 Validation of input RNA in cDNA synthesis 
 
An initial experiment resulted in high Ct values in the qPCR for some of the genes, and an 
additional experiment was therefore performed in order to validate the efficiency of the 
cDNA synthesis and find the best suitable concentration of cDNA to use in the RT-qPCR 
reactions. Two samples were selected, and for each sample three reactions were run with 
100, 350 and 1000 ng of input RNA diluted in PCR grade water to give a total volume of 14.2 
µL. A master mix was made using the High-Capacity Reverse Transcription Kit composed of 2 
µL 10x RT Buffer, 0.8 µl 25x dNTP mix (100 mM), 2.0 µL 10x RT Random Primers and 1.0 µL 
Multiscribe Reverse Transcriptase. The RNA was added to the master mix to a total volume 
of 20 µL for each of the samples, and the reaction was run at the thermal cycler GeneAmp 
PCR System 9700 using the thermal cycling program listed in Table 3.1.  
 
Table 3.1: Thermal cycling program for cDNA synthesis. 
Time Temperature 
10 minutes 25°C 
120 minutes 37°C 





The cDNA was diluted 1:2 in PCR-grade water and qPCR was performed on selected genes, 
each sample run in triplicate according to Table 3.2. qPCR was run on Light Cycler 480 Real-
Time PCR using the thermal cycling program listed in Table 3.3.   
Based on this experiment, 350 ng of input RNA and a 1:2 dilution of the resulting cDNA was 




RT-qPCR was performed to quantify the relative expression of target genes. IPO8 was used 
as a reference gene in order to normalize for differences in input mRNA among samples. 
IPO8 is a nuclear protein involved in import of proteins into the nucleus through the nuclear 
pore complex (NPC) and studies have found it among the most stably expressed genes in 
both SAT and VAT (Hurtado del Pozo, Calvo et al. 2010). Sequence of the reference and 
target genes primers can be found in Table 2.6. A reaction master mix was made, composed 
of 1740 µL SYBR GREEN Master reagent, 174 µL (20 µM) each of forward and reverse primer, 
and 957 µL PCR grade water. Then a mix was made for triplicates of each cDNA sample, 
containing 24,5 µL of the mastermix and 3,5 µL of cDNA. The mix was transferred to a 384-
well plate, 8 µL of each sample in triplicates. qPCR was run on Light Cycler 480 Real-Time 
PCR using the thermal cycling program listed in Table 3.3. The average expression levels for 
each triplicate was calculated relative to the expression of IPO8. Then the ∆∆Ct-approach 




Table 3.2: Reaction mix for qPCR 
Reagent Volume (µL) per sample 
Forward primer 0.4 
Reverse Primer 0.4 
SYBR GREEN master 4 





Table 3.3: The thermal cycling program used in qPCR reactions consist of one pre-









3.5 Isolation of PBMC from blood samples 
 
Blood was collected in heparin tubes and stored overnight at room temperature (RT). 15 mL 
of blood was diluted 1:1 in PBS then carefully layered on top of 15 mL Lymphoprep and 
centrifuged (25 min, 2000 rpm) to separate PBMC from plasma and red blood cells. The layer 
containing PBMC was isolated and washed by adding 45 mL PBS and centrifuged (6 minutes, 
1800 rpm), followed by staining for flow cytometry. 
 
3.6 Isolation of stromal vascular cells from adipose tissue biopsies 
 
Adipose tissue biopsies from SAT and VAT collected at Voss hospital were transported to our 
lab in 20 mL KRP buffer. Most of the biopsies were further processed after an overnight 
incubation at 4°C, while some were processed the same day. Larger blood vessels were 
excised from the biopsies and the remaining tissue cut into small pieces before enzymatic 
digestion with 0.66 mg/mL collagenase type I for 1 hour with shaking at 37°C. The tissue was 
filtered through 100 µm filters to remove connective tissue. The stromal vascular fraction 
was then isolated from the floating layer containing mature adipocytes, washed in PBS and 
centrifuged (5 minutes, 300g) before resuspending the pellet in PBS, followed by staining for 




 Time Temperature 
Pre-denaturation 5 minutes 95°C 
Denaturation 10 seconds  95°C 
Annealing 20 seconds 60°C 
Extension  30 seconds 72°C 
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Flow cytometric analysis 
3.7 Compensation 
 
Compensation controls were performed because of overlap in the emission spectra between 
several of the fluorochromes in the panel illustrated in Figure 3.2. For compensation, three 
drops of BD TM CompBeads containing Anti-Mouse Ig kappa and negative control beads 
were vortexed and mixed with 1.2 mL FACS buffer. Then, 50 µl of the beads was transferred 
into a 96-well plate and mixed with 0.5 µL of each of the antibodies listed in Table 2.1. 
Followed by a 20 minutes incubation in the dark at RT, the beads were washed twice with 
FACS buffer and centrifuged (3 minutes, 1600 rpm). Lastly, the beads were resuspended in 
200 µL FACS buffer and run on 18-color LSR Fortessa equipped with 407, 488, 561 and 640 
nm lasers. The compensation matrix was calculated in FlowJo 10.6.2 and adjusted manually.   
 
 
Figure 4.2. Spectral analysis of the flow cytometry panel (Biolegend). Spectral analysis of the 12-color panel used in the 
staining of PBMC and SVF from SAT and VAT. Excitation (dotted line), emission (line), laser (vertical line) and filter (vertical 







Table 4.4: Overview of the Macrophage panel used in staining for flow cytometry. Antibody 
targets and dead cell marker, fluorochromes, dilution factors, wavelength for excitation and 
filters used for detection are listed.  
Antibodies/marker  Fluorochrome Dilution  Excitation(nm) Filter/bandpass(nm)  
CD3 PE-Cy5 1:50 561 661/20 
CD11c PE-Cy7 1:100 561 780/60 
CD14 BV605 1:100 405 610/20 
CD16 BV711 1:100 405 710/50 
CD19 PE-Cy5 1:100 561 661/20 
CD40 PE 1:25 561 586/15 
CD44 PE-CF594 1:200 561 610/20 
CD45 AF700 1:400 639 730/45 
CD56 PE-Cy5 1:50 561 661/20 
CD163 AF647 1:100 639 670/30 
CD192 (CCR2) BV421 1:100 405 450/50 
CD206 BB515 1:200 488 530/30 
HLA-DR APC-Cy7 1:400 639 780/60 
DCM aqua Pacific Orange 1:100 405 525/50 
 
 
3.8 Staining of PBMC and SVF for flow cytometry 
 
Freshly isolated PBMC and SVF were counted under the microscope using Burker counting 
chamber, and three million cells from each sample were added to a 96-well plate for 
centrifugation (3 min, 1600 rpm). The cells were resuspended in 50 µL of the master mix, 
containing antibodies, dead cell marker Aqua-Pacific Orange and FACS buffer, as listed in 
Table 3.5. The cells were incubated in 20 minutes in the dark at RT, followed by washing 
twice in FACS buffer (150 & 200 µL), and centrifuged (3 min, 1600 rpm). In addition, 2 million 
cells from selected PBMC sample were applied as unstained negative control. The cells were 
fixated in 2% formaldehyde (v/v in PBS) for 15 minutes in the dark at RT followed by washing 
twice in FACS buffer and centrifuged (3 min, 1600 rpm). Lastly, the cells were resuspended in 
200 µL FACS buffer and applied on LSR Fortessa. The flow cytometry data was analyzed using 
FlowJo version 10.6.2. 
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Table 3.5: Volume of Antibodies and dead cell marker used for staining of PBMC and SVF for 
each sample, FACS buffer was added to a total volume of 50 µL. 











CD192 (CCR2) 0.50 
CD206 0.25 
HLA-DR 0.13 
DCM aqua 0.50 




3.9 Gating strategy for quantification of macrophages 
 
Gating was performed using FlowJo version 10.6.2. First, time versus forward scatter area 
was plotted, and a gate was drawn in order to exclude electronic noise. Then, forward 
scatter area was plotted against forward scatter height to gate for singlet cells, followed by 
gating for lymphocytes and monocytes/macrophages by plotting side scatter area against 
forward scatter area. Next, viable CD45 positive cells was gated for by plotting CD45 against 
the dead cell marker DCM-aqua. Then, a dump channel was applied by plotting CD11c 
against CD3, CD19 and CD56, and a gate was drawn to exclude the CD56, CD19 and CD3 
positive NK-cell, B- and T- lymphocytes respectively. Lastly, side scatter area was plotted 
against HLA-DR in order to gate for the HLA-DR positive macrophages and monocytes. The 
fraction of macrophages was normalized to total of CD45 positive viable cells. To calculate 
fraction of M1-, M2-like macrophages and monocytes of the total macrophage count, CD206 
was plotted against CD11c and the subpopulations were defined as monocytes (CD11c+ 
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CD206-), M1-like macrophages (CD11c+ CD206+) and M2-like macrophages (CD11c- 
CD206+). For each subpopulation, the fraction of CCR2, CD16 and CD163 expressing cells was 
calculated by plotting side scatter area against CCR2, CD16 and CD163, respectively and a 
gate was drawn on cells positive for the respective markers (supplementary Figure 1). The 
expression of CD14, CD40, CD44 and HLA-DR was calculated by applying the geometric mean 
function in FlowJo and results presented as log mean fluorescence intensity. 
 
Glucose uptake and lipolysis 
3.10 Isolation of mature adipocytes 
 
Subcutaneous and visceral adipose tissue biopsies arrived directly from surgery in 20 mL KRP 
buffer. First, the biopsies were cut clean of larger blood vessels and connective tissue, 
followed by weighing in from 1-1.5 gram of adipose tissue. The tissue was succumbed in 5 
mL of prewarmed (37°C) KRH buffer and cut into small pieces. Then, the tissue was 
incubated in 1 mg/mL collagenase I for 30-40 minutes at 37°C and shaking at 214 rpm. 
Followed by digestion, 5 mL of KRH buffer was added to dilute the enzyme, and the tissue 
was filtered through 400 µm filters and placed in 37°C water bath for 5 minutes to let the 
adipocytes separate from the SVF by floatation. The bottom layer, containing the SVF, was 
removed with a syringe and the adipocytes washed in 5 mL KRH buffer twice followed by 
incubation for 50-60 minutes at 37°C water bath to let the mature adipocyte float and pack 
densely as a top layer. Lastly, the KRH buffer was removed and the isolated adipocytes were 
diluted in KRH buffer to a 7.5% cell suspension.  
 
3.11 Glucose uptake 
 
The cell suspension was placed on a magnetic stirrer to ensure a homogenous suspension, 
and 200 µl of the cell suspension was transferred, and added 200 µL insulin diluted in KRH 
buffer to a final concentration of 10 nM. To measure basal glucose uptake, 200 µL of the cell 
suspension was added equal amount of KRH buffer. After 30 minutes of incubation at 37°C 
with shaking, 100 µL (9,25 kBq/mL) of C-14 glucose was added and incubated for another 30 
minutes. Lastly, 300 µL of the cell suspension was layered on top of Dionyl phthalate and 
centrifuged 1 minute at 12000 rpm to separate the cells from the medium. The samples 
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were then frozen at -20°C and transported to the Hormone laboratory in Bergen for further 
analyses.  The first samples from the first 13 patients were run in duplicates, while the last 
nine were run in triplicates. 
  
3.12 Scintillation counting 
 
The separation of cells resulted in three distinct layers, with the cells at the top separated 
from the medium by the oil layer in the middle composed of Dionyl phtalate. The tubes were 
taken directly from -20°C freezer and cut in two. The upper part containing the cells were 
transferred to a 25 mL scintillation tube together with 15 mL of Ultima Gold scintillation 
fluid. The disintegrations from the C-14 glucose taken up by the cells was then counted in 
PerkinElmer Tri-Carb 4910 TR Liquid Scintillation Analyzer at 5 minutes with 1-minute pre-
count delay.  
 
3.13 Lipolysis assay 
 
For the first six patients samples the cell suspension was diluted to 3.75%, and for the 
seventh patient onward a 7.5% cell suspension was used. To measure both stimulated and 
basal lipolysis, 400 µL of the cell suspension was incubated both with and without 10 nM of 
the β-adrenoreceptor agonist, isoprenaline, for 30 minutes at 37°C while shaking. The cell 
suspension was then placed on ice for 30 minutes to stop the assay and let the adipocytes 
float. 160 µL of the glycerol containing medium was then transferred by a thin pipette and 
frozen at -20°C until further analyses. All samples were run in duplicates. 
 
3.14 Glycerol detection assay 
 
In periods of energy demands, adipocytes mobilize their fat store by hydrolytic cleavage of 
TAGs, releasing non-esterified fatty acids and glycerol into the circulation in a 3:1 
stoichiometry (Lass, Zimmermann et al. 2011). To quantify the lipolysis, we measured 
glycerol released from the cells into the medium using the Free Glycerol detection Reagent 
(Sigma Aldrich). The Glycerol Reagent generates a quinoneimine dye using coupled enzyme 
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reactions. The dye shows an absorbance maximum at 540 nm and the absorbance is directly 
proportional to the free glycerol concentration of the sample.  
For each of the samples from the lipolysis assay, 30 µL was mixed with 100 µL Free Glycerol 
reagent and incubated for 15 minutes in dark at RT, in addition to a dilution series of 0.125, 
0.25, 0.50, 1.00, and 2.00 mM glycerol in KRH buffer and a sample of ddH2O to serve as 
blank. The dilution series were used to set up a standard curve in order to calculate the 
glycerol concentrations of the samples (equation 3.1). The absorbance was measured at 540 
nm in spectrophotometer Spectra Max Plus 384.  
 
Equation 3.1:              
(𝑨𝒔𝒂𝒎𝒑𝒍𝒆−𝑨𝒃𝒍𝒂𝒏𝒌)
(𝑨𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅−𝑨𝒃𝒍𝒂𝒏𝒌)
 𝒙 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅 
 
 
3.15 Statistical analysis  
 
All statistical analyses were performed in R studio. Shapiro-Wilk test was performed to check 
for normality and all variables from flow cytometry, gene expression, lipolysis and glucose 
uptake data were log transformed. Two-sided paired t-test was performed to compare 
macrophage populations and gene expression between SAT and VAT. Paired Wilcoxon 
Signed-rank test was performed to compare lipolysis and glucose uptake between SAT and 
VAT. It was performed Pearson and Spearman correlation analysis between flow cytometry, 














4.1 Comparison of monocytes, M1- and M2-like macrophages in SAT and VAT 
 
Flow cytometry was used to assess whether there are fat depot specific differences with 
respect to macrophage infiltration. PBMC were isolated from human blood by density 
gradient centrifugation and the SVF obtained from SAT and VAT by collagenase digestion 
from a cohort of 21 severely obese patients undergoing bariatric surgery. Gating strategy to 
isolate total macrophage and monocyte population from one representative VAT sample is 
depicted in Figure 4.1.A, and gating strategy to quantify the fraction of monocytes, M1-like 
and M2-like macrophages from one representative PBMC, SAT and VAT sample is depicted in 




Figure 4.2. Gating scheme for isolating monocytes, M1- and M2-like macrophages. A: First a time gate was applied to 
exclude electronic noise, then forward scatter area is plotted against forward scatter height to gate for single cells excluding 
any doublets, followed by plotting forward scatter area versus side scatter area to gate for lymphocytes and monocytes. 
Then cells positive for CD45 and negative for the dead cell marker DCM aqua was gated for followed by plotting CD3-CD19-
CD56 PE-Cy5 against CD11c PE-Cy7 to exclude T- and B-lymphocytes and NK-cells respectively. Lastly HLA-DR APC-Cy7 was 
plotted against side scatter area to isolate the HLA-DR positive macrophages and monocytes. B: CD11c PE-Cy7 was plotted 
against CD206 BB515 to quantify the fraction of the CD11c+ CD206+ M1-like macrophages, CD11c- CD206+ M2-like 





The macrophages and monocytes were isolated based on their expression of CD45 and HLA-
DR, and absent of CD3, CD19 and CD56 expression. The different macrophage populations 
were then isolated and categorized based on the expression of CD11c and CD206; M1-like 
macrophages CD11c+CD206+, M2-like macrophages CD11c-CD206+ and monocytes 
CD11c+CD206-. First, we assessed the fraction of macrophages from the total of CD45+ cells 
in PBMC, SAT and VAT. We found that there was a significant (p<0.001)  higher number 
(mean %, ± sd) of total macrophages in SAT (22.7 ± 8.0) and PBMC (23.5 ± 9.8) compared to 
VAT (10 ± 5.3) (Figure 4.2.A). The higher fraction in total macrophage and monocyte 
population seemed to arise from a significant higher fraction of monocytes in SAT versus 
VAT (Figure 4.2.B), indicating a higher infiltration of monocytes into SAT. However, the 
number of M2-like macrophages were higher in VAT than in SAT, but not enough to account 
for the difference in total macrophage and monocyte content. In PBMC, M2-like 
macrophages were only detected in a few samples and at a very low number. The fraction of 
M1-like macrophages was similar between SAT and VAT, and only present at a very low 
amount in peripheral blood (0.82 ± 0.7) which mostly contained the CD11c positive 
monocytes.    
 
 
Figure 4.3.  Macrophage populations from PBMC, SAT and VAT. Scatter plot showing; A: The fraction of macrophages and 
monocytes in PBMC, SAT and VAT from the total of CD45+ viable cells isolated. B: The fraction of monocytes, M1-like and 





4.2 Characterizing the phenotype of monocytes, M1-like and M2-like macrophages 
 
In order to assess whether the CD11c+CD206+ M1-like and CD11c-CD206+ M2-like 
macrophages exhibit a pro- and anti-inflammatory phenotype respectively, the expression of 
the established pro-inflammatory surface receptors such as CD14, CD16, CD40, CD44, CCR2, 
HLA-DR and the anti-inflammatory receptor CD163 was assessed by flow cytometric analysis. 
Most notable was the significant higher number of cells expressing the chemotactic receptor 
CCR2 (Lim, Yuzhalin et al. 2016) among the M1-like macrophages compared to the M2-like 
macrophages, in both SAT and VAT. Similarly, a high fraction of monocytes in SAT and VAT 
expressed CCR2 suggesting that these cells are recruited to the adipose tissue. There was 
also a significant higher number of the M1-like macrophages in VAT (90.9 ± 8.8) versus SAT 
(74,3 ± 27,5) expressing CCR2 suggesting that a higher fraction of the macrophages in VAT 
are recruited pro- inflammatory cells and not arise from proliferating resident cells. CD44, a 
receptor that is known to be involved in cell migration but also proliferation and activation 
of cells (Senbanjo and Chellaiah 2017), were found to be higher expressed on M1-like 
macrophages and monocytes in both SAT and VAT compared to M2-like macrophages, 
supporting that these cells are infiltrating pro-inflammatory cells. CD14, a pattern 
recognition receptor known to be involved in innate immune responses as a co-receptor for 
TLR`s (Kelley, Lukk et al. 2013) was higher expressed on both M1-like and M2-like 
macrophages compared to monocytes in VAT, and significantly higher on the M2-like 
macrophages in VAT versus M2-like macrophages in SAT, supporting a more inflammatory 
phenotype in VAT. However, no significant differences were found between M1-like and M2-
like macrophages. CD163, which is best known for its homeostatic and anti-inflammatory 
functions (Etzerodt and Moestrup 2013), was significantly higher expressed on M2-like 
versus M1-like macrophages in VAT supporting an anti-inflammatory phenotype of M2-like 
macrophages. However, this was not observed in SAT. Additionally, monocytes expressed 
significantly lower levels of CD163 in all tissues. There is no significant difference in the 
expression levels of the pro-inflammatory receptors CD16, CD40 and HLA-DR between 
monocytes, M1-like and M2-like macrophages and between the different tissues. However, 
a large variation in the expression levels was observed, indicating different subpopulations 
with pro- and anti-inflammatory characteristic within the populations of M1- and M2- like 
macrophages. The intensity plot in Figure 4.3.H from one representative VAT sample are 
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illustrating the vast differences in expression of CCR2 on monocytes and M1-like 
macrophages compared to M2-like macrophages.  
 
 
Figure 4.4. Expression of surface receptors on Monocytes (Mo), M1-like and M2 like macrophages. A, D and C: Scatter plot 
showing the percentage of cells expressing the proteins CCR2(A), CD44(B), CD14(C) and CD163(D) on Monocytes (grey), M1-
like (red) and M2-like (blue) macrophages. B, C, F and G: Scatter plot showing the log mean fluorescence intensity (MFI) 
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from staining of CD44 (B), CD14 (C) and CD40(F), and HLA-DR (G) on Monocytes, M1-like and M2-like macrophages in PBMC, 
SAT and VAT. H: Intensity plot from the staining of proteins in A-G from a representative VAT sample. Black dot represents 
mean and error bar represent SEM (n=21). * = p<0.05, ** = p<0.01, *** = p<0.001.  
 
 
4.3 Quantifying M1- and M2-like macrophages in normal weight, obese and T2DM subjects 
 
Next, we wanted to investigate whether there was a different in composition of M1- and 
M2-like macrophages in SAT and VAT of normal weight subjects, obese or obese subjects 
diagnosed with T2DM. We included 3 normal weight subjects undergoing cholecystectomy 
to represent the control group and identified 9 subjects diagnosed with T2DM from our 
cohort of severely obese bariatric surgery patients. Data from 4 of the subjects in the obese 
group were excluded from the analysis due to a low number of cells. We observed no 
significant differences in the fraction of each cell type within SAT or VAT between normal 
weight, obese or subjects with T2DM (Figure 4.4).  
 
 
Figure 4.5. Macrophage populations in SAT and VAT of normal weight (control), obese and T2DM subjects. Scatter plot 
showing the percentage of M1- and M2-like macrophages of the total macrophage population In SAT and VAT in normal 






4.4 Depot specific associations of ATM populations with clinical parameters.  
 
We also wanted to investigate whether the composition of pro-inflammatory M1-like and 
anti-inflammatory M2-like macrophages from adipose tissue was associated with clinical 
parameters relevant for systemic insulin resistance or the lipid profile, and markers of 
inflammation measured in peripheral blood. For 4 of the subjects, we were not able to 
provide clinical data. The analysis includes 16 subjects in total from the control group, obese 
and obese with T2DM. All variables were log transformed due to non-normally distributed 
data and there was performed a Pearson correlation analysis (Figure 4.5). Interestingly, the 
pro-inflammatory M1/M2-ratio in VAT was significantly correlated with the circulating 
markers of inflammation, CRP (R2 = 0.535, p = 0.032) and leukocytes (R2 = 0.763, p = 0.0006). 
Similarly, there was a significant, negative correlation of M2-like macrophages in VAT with 
CRP and leukocytes, indicating that macrophage polarization towards a more pro-
inflammatory phenotype is associated with systemic inflammation. Moreover, there was a 
positive, but non-significant correlation of leukocytes and monocytes in VAT, suggesting a 
higher infiltration of monocytes into VAT than in SAT in the setting of inflammation. Insulin 
correlated positive with the anti-inflammatory M2-like macrophages (R2 = 0.533, p = 0.033) 
in SAT and negatively with the pro-inflammatory M1/M2-ratio (R2 = -0.569, p = 0.021). The 
same association was seen for HOMA-IR, although not significant (R2 = 0.437, p = 0.090 and 
R2 = -0.474, p = 0.063). Interestingly, this association was not seen in VAT. There were no 
significant correlations between the macrophage populations and the lipid profile in the 
blood or BMI and age. Because some of the variables were not normally distributed, we also 
performed a Spearman correlation, which showed the same trends, although none remained 




Figure 4.6. Correlation plot of macrophage populations versus clinical parameters. Pearson correlation of Monocytes, M1- 
, M2-like macrophages and M1/M2 ratio with clinical parameters measured in peripheral blood (n=16). Size and color of 
circles indicate correlation coefficients and squares indicate non-significant correlations (p>0.05) 
 
4.5 Depot specific differences in expression levels of pro- and anti-inflammatory genes 
 
In addition to analyzing the inflammatory phenotype of macrophages in adipose tissue, we 
wanted to assess how the expression level of genes relevant for adipose tissue inflammation 
differed between SAT and VAT in a cohort of 54 severely obese subjects. The expression 
levels were quantified at the mRNA level by RT-qPCR. The fold change (2-∆∆Ct) was calculated 
relative to IPO8 as reference gene and normalized to the mean of the SAT samples, and then 
log transformed due to non-normally distributed data. There was no significant difference in 
the expression levels of the pro-inflammatory genes TNF (Figure 4.6.A), IFN-gamma (C) and 
IL6 (D) between SAT and VAT. However, the chemotactic ligand MCP-1 (B) (Kanda, Tateya et 
al. 2006) and the macrophage associated protein CD68 (H) was significantly higher expressed 
in SAT, which supports the findings from the flow cytometry analysis (Figure 4.2.A) that total 
macrophage content is higher in SAT than VAT. The lipid receptor TREM2 (Jaitin, Adlung et 
al. 2019) is considered to have an anti-inflammatory role in maintaining metabolic 
homeostasis. We observed that TREM2 was significantly higher expressed in SAT, suggesting 
a less inflammatory profile in SAT versus VAT. Contrary, CD163 (I), which is also considered 
to be involved in anti-inflammatory responses (Etzerodt and Moestrup 2013), was 
significantly higher expressed in VAT than in SAT, contradicting the suggested difference in 
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the inflammatory profile between SAT and VAT. There were no significant differences in the 




Figure 4.7. Relative expression level of pro- and anti-inflammatory genes between SAT and VAT. The expression levels of 
the pro- inflammatory genes TNF (A), MCP1 (B), IFN-gamma (C), IL6 (D), the anti-inflammatory genes TREM1 (E), TREM2 (F), 
The adipocyte specific transcription factor Nr4A1 (G) and the macrophage specific proteins CD68 (H) and CD163 (I) were 
analyzed by qPCR and results are presented as log transformed fold change (2-∆∆Ct) of the target gene relative to the 
reference gene IPO8. The expression levels were normalized to the mean of the SAT samples. Red line indicates the mean 




4.6 Co-expression of pro- and anti-inflammatory genes within and between fat depots 
 
Next, we wanted to assess the inflammatory profile in SAT and VAT by analyzing patterns of 
co-expression among the pro- and anti-inflammatory genes. A strong significant correlation 
between the macrophage associated protein CD68 with CD163, TREM1, TREM2 and MCP1 in 
SAT could indicate that the immune cells infiltrating SAT present with an anti-inflammatory 
gene expression pattern. (Figure 4.7.A) CD68 also correlate strongly with CD163 and TREM2 
in VAT but not with MCP1 or TREM1. In addition, NR4A1, which expression is found to be 
associated with impaired adipose tissue plasticity and inflammation (Zhang, Federation et al. 
2018), was significantly correlated with the pro-inflammatory genes TNF, IFN-γ and IL6 
supporting an inflammatory response in VAT (Figure 4.7.B) related to impaired adipose 
tissue plasticity. We also wanted to assess whether upregulation of pro- or anti-
inflammatory genes in one fat depot is reflected by upregulation of the same gene in the 
other depot, or is reflected by up- or down regulation by one of the other genes (Figure 4.8). 
In fact, the expression of NR4A1 and the pro-inflammatory genes TNF, MCP1, IFN-γ, and IL6 
were found to exhibit a significantly correlated expression between SAT and VAT. Most 
prominent was the strong correlation of IFN-γ, which is known as the most important 
cytokine for activation of pro-inflammatory M1-like macrophages (O'Rourke, White et al. 
2012). This suggests that inflammation in one fat depot was reflected by inflammation in the 
other depot as well. Interestingly, the upregulation of NR4A1 in one depot was reflected by 
upregulation of IFN-γ in the other depot, supporting the notion that NR4A1 plays a role in 





Figure 4.8. Co-expression of pro- and anti-inflammatory genes in SAT and VAT. Correlation plot showing the Person 
correlation between expression levels of the Pro-inflammatory genes TNF, MCP1, IFN-gamma, IL6, the anti-inflammatory 
genes TREM1, TREM2, the transcription factor Nr4A1 and the genes for the macrophage associated receptors CD68 and 
CD163 in SAT (A) and VAT (B) (n=54). Size and color of circles indicate correlation coefficients and squares indicate 





Figure 4.8. Correlation between pro- and anti-inflammatory genes expressed in SAT and VAT. Correlation plot indicating 
the Pearson correlation of the Pro- inflammatory genes TNF, MCP1, IFN-gamma, IL6, the anti-inflammatory genes TREM1, 
TREM2, the transcription factor Nr4A1 and the genes for the macrophage associated receptors CD68 and CD163 expressed 
in SAT and VAT (n=54). Size and color of circles indicate correlation coefficients and squares indicate insignificant 




4.7 Associations between the expression levels of pro- and anti-inflammatory genes with 
clinical data. 
 
In order to establish whether a pro-inflammatory gene expression pattern in adipose tissue 
is associated with systemic insulin resistance, an unhealthy lipid profile or markers of 
inflammation measured in peripheral blood, a correlation analysis was performed. 
Interestingly, HOMA-IR and HbA1C, a measure of insulin resistance and glucose intolerance, 
respectively, and triglyceride levels were all found to be positively correlated with CD68 and 
CD163 expression in SAT, indicating a higher number of macrophages in SAT of insulin 
resistant subjects. TREM2 expression in SAT also correlated with HOMA-IR (R2 = 0.408, p = 
0.002) and HbA1C (R2 = 0.312, p = 0.024) suggesting a more anti-inflammatory profile in SAT 
of insulin resistant subjects. Interestingly, IL6 correlated negatively with HOMA-IR in SAT (R2 
= -0.305, p = 0.028), and a similar trend was observed in VAT (R2 = -0.244, p = 0.081), 
although not significant. Moreover, IL6 expression in SAT (R2 = 0.284, p = 0.041) and VAT (R2 
= 0.255, p = 0.067) associated positively with HDL, an indicator of a healthy lipid profile, 
which supports the notion of a pleiotropic function of this cytokine beyond its role in 
inflammation (Kurauti, Costa-Junior et al. 2017). It is noteworthy that there are no 
associations of HOMA-IR, HbA1C or triglycerides with CD68 and CD163 or the anti-
inflammatory gene TREM2 in VAT. A significant correlation of MCP1 (R2 = 0.412, p = 0.002) 
with BMI suggests a higher infiltration of monocytes into VAT in the setting of obesity. In 
SAT, however, BMI only showed a significant association with CD68.  It is also intriguing that 
expression of NR4A1 (R2 = 0.294, p = 0.034) and also CD163 in VAT correlated positively with 
CRP. In addition, there, was a positive but not significant association of the pro-inflammatory 
genes TNF, MCP1 and IFN-gamma in VAT with CRP, suggesting a link between systemic 
inflammation and AT inflammation in VAT.  
To summarize, this analysis suggests that insulin resistance and an unhealthy lipid profile is 
characterized by a pattern of anti-inflammatory gene expression in SAT and an absent of this 
pattern in VAT, supporting the conclusion from the flow cytometry data that insulin 
resistance is associated with a higher proportion of M2-like macrophages in SAT, which is 
not seen in VAT. The results from the gene expression analysis also suggest that a pro-
inflammatory gene expression pattern in VAT is associated with systemic inflammation, 
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which supports the conclusion from the flow cytometry data that the pro-inflammatory 
M1/M2-ratio are associated with systemic inflammation.  
 
Figure 4.9. Correlation plot of pro- and anti-inflammatory gene expression in SAT and VAT with metabolic parameters.    
Correlation plot indicating the Pearson correlation of the Pro- inflammatory genes TNF, MCP1, IFN-gamma, IL6, the anti-
inflammatory genes TREM1, TREM2, the transcription factor Nr4A1 and the macrophage associated receptors CD68 and 
CD163 expressed in SAT and VAT with metabolic parameters (n=54). Size and color of circles indicate correlation coefficients 




4.8 Comparison of the rate different adipose tissue depots mobilize fatty acids. 
 
Further we wanted to assess functional characteristics of isolated mature adipocytes. From a 
cohort of 21 severely obese patients undergoing bariatric surgery, the rate of glycerol 
release were measured in freshly isolated adipocytes from SAT and VAT, with the aim of 
comparing the rate in which adipocytes mobilize their fatty acids through lipolysis between 
the two depots. A correlation analysis (Figure 4.11) was also performed to assess whether 
the degree of lipolysis associated with systemic insulin resistance, metabolic dysregulation 
or measures of systemic inflammation.  A pairwise comparison revealed that the basal rate 
of lipolysis was similar between the two tissues and there was a significant increase in 
response to isoprenaline stimulation in both tissues (Figure 4.11). As expected, the rate of 
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which isoprenaline stimulation increased lipolysis was significantly higher in VAT (Wilcox test 
p<0.001) indicating that fatty acids from VAT is first mobilized in periods of energy demand 




Figure 4.10. The rate of basal and stimulated lipolysis in SAT and VAT. A: Boxplot showing the rate of lipolysis in SAT and 
VAT in basal and in isoprenaline stimulated conditions measured by glycerol release. B: Violin plot showing the increase in 
rate of lipolysis in response to isoprenaline stimulation in SAT and VAT (n=21). ** = p<0.01, *** = p<0.001.   
 
The correlation analysis revealed a negative correlation of LDL (R2 = -0.545, p = 0.011) and 
total cholesterol levels (R2 = -0.497, p = 0.028) in blood with the lipolytic response in VAT. 
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This was not observed in SAT, instead the lipolytic response in SAT was correlated with 
triglycerides (R2 = 0.536, p = 0.012), suggesting a negative contribution of the lipolytic 
response in SAT with respect to metabolic syndrome. Insulin levels and HOMA-IR also 
associated negatively with both basal (R2 = -0.536, p = 0.012 & R2 = -0.479, p = 0.027) and 
stimulated lipolysis (R2 = -0.619, p = 0.002 & R2 = -0.579, p = 0.005) in VAT, but not to the 
lipolytic response. This contradicts the notion that elevated basal levels of lipolysis in VAT is 
exacerbating insulin resistance and T2DM by promoting ectopic lipid accumulation (Bodis 
and Roden 2018). 
 
 
Figure 4.11. Correlation plot of lipolysis versus clinical parameters. Correlation plot indicating Person correlation between 
the rate of lipolysis and metabolic parameters measured in blood in addition to BMI and Age (n=21). Size and color indicate 
correlation coefficients and squares indicate insignificant associations (p>0.5). 
 
4.9 Glucose uptake and insulin sensitivity between different adipose tissue depots. 
 
Next, we assessed the glucose uptake and insulin sensitivity by measuring uptake of C-14 
glucose in freshly isolated adipocytes from the same cohort as the lipolysis assay including 
one additional sample. Uptake of the radioactive glucose was measured by scintillation 
counting and the results presented as disintegrations per minute in Figure 4.12.A. Both 
adipose tissue depots responded significantly to insulin stimulation, and as expected both 
the basal and stimulated glucose uptake was elevated in VAT compared with SAT in our 
cohort (Westergren, Danielsson et al. 2005). The response to insulin stimulation on glucose 







Figure 4.12. Glucose uptake in isolated adipocytes from SAT and VAT. Uptake of C-14 glucose in freshly isolated adipocytes 
from SAT and VAT of severely obese subjects were measured by scintillation counting and results presented as 
disintegrations per minute. A: Boxplot showing the degree of glucose uptake in SAT and VAT under basal and insulin 
stimulated conditions. B: Violin plot comparing the fold increase in glucose uptake in response to insulin stimulation in SAT 






We also performed a correlation analysis of glucose uptake and insulin sensitivity in adipose 
tissue versus metabolic parameters measured in blood in order to reveal whether insulin 
resistance and glucose intolerance in adipose tissue is associated with systemic measures of 
insulin resistance or other indicators of metabolic syndrome (Figure 4.13). We found a 
significant correlation of basal glucose uptake in VAT with HDL (R2 = 0.459, p = 0.036) 
suggesting a beneficial effect on the lipid profile in blood. Moreover, a negative, but not 
significant, correlation of glucose uptake with glucose levels in blood was found, supporting 






Figure 4.13. Correlation plot of glucose uptake versus clinical parameters. Correlation plot indicating Person correlation of 
glucose uptake and insulin sensitivity versus metabolic parameters measured in blood in addition to BMI and Age (n=22). 










Both lipolysis and glucose uptake are essential processes in regulating the whole-body 
energy homeostasis. Therefore, we wanted to investigate how the two different processes 
associated by doing a correlation analysis (Figure 4.14). The results showed that the 
response of glucose uptake on insulin stimulation associated negatively with lipolytic 
response in VAT (R2 = -0.459, p = 0.036). Contrary, the basal level of lipolysis showed a 
positive association with insulin sensitivity (R2 = 0.440, p = 0.046) in VAT, that contradicts 
previous reports showing that insulin resistance in VAT is associated with elevated levels of 
basal lipolysis (Bodis and Roden 2018).  
 
 
Figure 4.14. Correlation plot of glucose uptake versus lipolysis. Person correlation of glucose uptake versus the rate of 













Adipose tissue inflammation has been pointed out as a plausible mechanistic link connecting 
obesity and associated diseases such as insulin resistance and T2DM. It is now widely 
accepted that macrophages and other immune cells infiltrate adipose tissue at a high rate 
and are contributing to a chronic state of inflammation in the tissue. However, the relative 
contribution of different immune cell populations is still heavily debated, and there is a lack 
of consensus with respect to which molecular players are contributing to the worsened 
metabolic phenotype. The aim of this thesis was to investigate fat depot-specific differences 
with respect to adipose tissue inflammation, and to phenotypically characterize the ATM 
populations. We also wanted to study whether skewing towards a more pro-inflammatory 
macrophage population is associated with systemic insulin resistance, inflammation, or an 
unhealthy lipid profile. Furthermore, we performed functional analyses in freshly isolated 
mature adipocytes to investigate how glucose uptake and lipolysis are associated with 
systemic insulin resistance, inflammation and lipid profile. 
 
5.1 SAT contains a higher fraction of ATM than VAT 
 
Insulin resistance has been associated with infiltration of macrophages in both SAT and VAT, 
observed both in HFD fed mice and obese humans (Bodis and Roden 2018). In particular, 
infiltration into VAT has been associated with a worsened metabolic phenotype (Lebovitz 
and Banerji 2005), although the relative contribution of each fat depot has been heavily 
debated.  In our study we found that SAT contains a significant higher fraction of total 
macrophages and monocytes than VAT. This was also found in another study that involved 
29 obese bariatric surgery patients where macrophages and monocytes were also 
characterized by the expression of CD11c and CD206 (Wentworth, Naselli et al. 2010). We 
also assessed the gene expression in SAT and VAT and found that CD68 and MCP1, but also 
TREM2 is higher expressed in SAT than VAT, which supports that macrophages are more 
abundant in SAT. Conversely, a study done in 55 morbidly obese gastric surgery patients, 
where the surface protein HAM56 was used to characterize macrophages by 
immunohistochemistry, found the number of infiltrating macrophages to be twice as high in 
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VAT as in SAT (Cancello, Tordjman et al. 2006), whereas a study performed in 10 lean 
cholecystectomy patients failed to find any differences between SAT and VAT (Koenen, 
Stienstra et al. 2011). Moreover, our gene expression data showed that CD163 are more 
highly expressed in VAT than in SAT, which may rise doubt about whether the macrophages 
are likely to be more abundant in SAT. The discrepancy between different studies reporting 
ATM compositions highlights the need for a more unifying concept on how to best identify 
ATMs. 
 
5.2 Alternatively activated M2-like macrophages are more abundant in VAT than SAT 
 
It is well known that there are different subsets of macrophages in adipose tissue with 
different functional properties, and earlier studies have characterized a subset of 
CD11c+CD206+ ATM that shows features of classically activated macrophages (M1) and a 
subset of CD11c-CD206+ ATM that shows features of alternatively activated macrophages 
(M2) (Wentworth, Naselli et al. 2010). We looked at how these populations of macrophages 
were distributed in the two fat depots and found the alternatively activated M2-like 
macrophages to be significantly more abundant in VAT. These findings were supported by 
the gene expression analysis showing a higher expression of the anti-inflammatory marker 
CD163 in VAT. Contrary, the monocytes were more abundant in SAT compared to VAT. 
However, there was no difference in the number of M1-like macrophages between SAT and 
VAT.  
If inflammation in VAT is more closely associated with insulin resistance than in SAT, we 
could expect a higher number of the pro-inflammatory M1 macrophages in VAT of subjects 
with T2DM. We therefore analyzed the composition of M1 and M2 macrophages after 
separating the subjects diagnosed with T2DM from our cohort of severely obese subjects. In 
addition, we included three subjects undergoing cholecystectomy with a BMI in the range 
22-29 kg/m2 to represent the control group. Somewhat unexpected, we could not find any 
significant differences in number of M1- or M2-like macrophages between the control 
group, the T2DM patients and the obese group without T2DM. A small sample size could 




5.3 High expression of CCR2 by M1-like macrophages supports their pro-inflammatory 
identity. 
 
There is still a debate on how to best characterize pro- and anti-inflammatory macrophages 
in adipose tissue, and studies have shown that the alleged CD11c+CD206+ M1-like 
macrophages also exhibit characteristics of anti-inflammatory M2-like macrophages such as 
high mitochondrial copy number and high expression of the anti-inflammatory cytokine IL-10 
(Vats, Mukundan et al. 2006), (Mantovani, Sica et al. 2004), (Kim, Zhang et al. 2004). 
Therefore, we sought to confirm the pro- and anti-inflammatory phenotype of M1-like and 
M2-like macrophages from SAT and VAT by the expression of additional surface receptors. 
Most strikingly, the pro-inflammatory marker CCR2 was found to be highly expressed by M1-
like macrophages and to some extent on the monocytes but was almost absent on the M2-
like macrophages. Interestingly, the level of ATM CCR2 expression varied between the fat 
depots, with CCR2 consistently expressed by a higher fraction of the M1-like macrophages in 
VAT, while there was a great variation in the number of CCR2 expressing M1-like 
macrophages in SAT, which supports a more pro-inflammatory profile in VAT.  A similar 
pattern was observed for the monocytes. CD44 was also found to be higher expressed by 
both M1-like macrophages and monocytes in both SAT and VAT. CD44 is also a receptor 
involved in cell migration and an important mediator in the cell responding to pro-
inflammatory stimuli (Lim, Yuzhalin et al. 2016), (Senbanjo and Chellaiah 2017). Studies have 
found the ratio of anti-inflammatory M2-like macrophages versus M1-like macrophages to 
be significantly higher in adipose tissue of CD44 knock-out mice fed a HFD, which supports 
that CD44 is facilitating infiltration of M1-like macrophages into adipose tissue (Kang, Liao et 
al. 2013). Interestingly, the M1-like macrophages displayed a great variation in expression 
levels of CD44 between the subjects. The alleged anti-inflammatory marker CD163 was 
highly expressed in both M1-like and M2-like macrophages in SAT and VAT, and showed only 
a marginal higher expression in M2-, relative to M1-like macrophages in VAT. This suggests 
that CD163 is probably not an appropriate marker to distinguish between pro- and anti-
inflammatory macrophages in adipose tissue. In conclusion, the high expression of CCR2 
supports a pro-inflammatory identity of M1-like macrophages. Moreover, in animal models 
of obesity, it has been found that silencing CCR2 reduces macrophage number and 
inflammation in adipose tissue and also improve insulin sensitivity (Kim, Chung et al. 2016). 
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However, the high variability in expression of CD14, CD16, CD40, CD44 and HLA-DR on both 
M1- and M2-like macrophages suggests a broad spectrum of activation states or the 
existence of different subgroups of cells within these cell populations.   
 
5.3 Elevated levels of insulin and HOMA-IR are associated with M2-like macrophages in 
SAT 
 
Similar studies have shown that insulin resistance is associated with increased numbers of 
CD11c+CD206+ M1- like macrophages and also with the pro-inflammatory M1/M2 ratio in 
both SAT and VAT (Wentworth, Naselli et al. 2010). We performed a person correlation 
analysis to investigate whether the different macrophage populations or the M1/M2 ratio 
are associated with systemic insulin resistance or other clinical parameters relevant for 
metabolic syndrome in our cohort. Surprisingly, the M1/M2 ratio in SAT correlated 
negatively with HOMA-IR. Although this association was not significant, there was clearly a 
trend, which was supported by a strong significant negative association of insulin levels with 
the M1/M2 ratio and the positive association of CD11c-CD206+ M2-like macrophages with 
insulin. Similar associations between insulin resistance and macrophage populations were 
not found in VAT. The gene expression analysis supports that insulin resistance is associated 
with increased number of M2-like macrophages in SAT by the positive association of CD68, 
CD163 and TREM2 with HOMA-IR and HbA1C, which were not detected in VAT. Although 
CD68 and CD163 are not specific for M2-like macrophages, TREM2 has been recognized for 
its role in anti-inflammatory M2-like macrophages by its ability to suppress inflammatory 
responses by blocking toll-like receptor signaling (Turnbull, Gilfillan et al. 2006), (Zhong, 
Chen et al. 2015) and subsequent secretion of the proinflammatory cytokines IL-1b, IL6 and 
iNOS. Moreover, studies in mice have found TREM2 to be a positive regulator of 
adipogenesis, and TREM2 KO-mice have been shown to have increased obesity, insulin 
resistance and impaired adipose tissue remodeling (Liu, Li et al. 2019). This suggests that 
TREM2-expressing M2-like macrophages could be involved in a protective mechanism to 
cope with insulin resistance by regulating adipogenesis and inflammation (Liu, Li et al. 2019), 
and our results indicate that this mechanism may be less active in VAT.    
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We also found that M1/M2 ratio in VAT strongly associated with CRP and leukocytes while 
M2 macrophages associated negatively with the same parameters, which supports the 
hypothesis that adipose tissue inflammation can promote systemic inflammation (Fontana, 
Eagon et al. 2007). This was further supported by the gene expression analysis showing that 
NR4A1, TNF, MCP1 and IFN-γ expression in VAT associated with systemic CRP levels. 
Contrary, from experiments in rats it has been reported that CRP are able inhibit the 
differentiation of monocytes into M2-like macrophages and instead promote polarization of 
monocytes and M2-like macrophages into a M1-like phenotype suggesting that systemic 
inflammation can promote adipose tissue inflammation (Devaraj and Jialal 2011). However, 
the fact that there was no correlation between M1/M2 ratio in SAT with neither CRP nor 
leukocytes raise doubt about the direction of causality.  
 
5.3 Pro-inflammatory gene expression is reflected in both fat depots 
 
The expression levels of the pro-inflammatory genes, TNF, MCP1, IFN-γ, IL6, and also the 
transcription factor NR4A1, were strongly associated between SAT and VAT suggesting that 
inflammation in one fat depot is reflected by inflammation in the other depot as well. 
Although the pro-inflammatory gene expression pattern was mostly similar between the two 
depots, TREM1 deviated from this pattern by its strong association with the anti-
inflammatory receptor CD163 in SAT.  In VAT, there was a stronger association of the 
transcription factor NR4A1 with the pro-inflammatory genes TNF, IFN-γ and IL6 than in SAT. 
It has been suggested that adipose tissue inflammation and insulin resistance arise when the 
adipocyte hyperplastic response is insufficient to accommodate the metabolic stress of 
caloric excess as observed in both obesity and lipodystrophy (Wang, Tao et al. 2013), 
(Pasarica, Xie et al. 2009). NR4A1 has been described as a negative regulator of adipocyte 
hyperplasia suggesting a link to adipose tissue inflammation and T2DM (Zhang, Federation et 
al. 2018). The association with pro-inflammatory genes in our study supports a role for 
NR4A1 in adipose tissue inflammation, although we could not find an association with insulin 
resistance (measured by HOMA-IR). Interestingly, the expression of IL6 negatively correlated 
with HOMA-IR in both SAT and VAT, contradicting the traditional viewpoint of IL6 as an 
important pro-inflammatory mediator in promoting insulin resistance (Bastard, Maachi et al. 
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2002). While it was earlier believed that secreted IL6 had mostly negative effect on glucose 
homeostasis by affecting insulin signaling and promoting insulin resistance, particularly in 
the liver (Klover, Zimmers et al. 2003). Recent studies have discovered an important role of 
IL6 in regulating expression of insulin degrading enzyme and facilitating insulin clearance to 
prevent sustained exposure to high levels of insulin and consequently desensitization of the 
signaling pathway (Kurauti, Costa-Junior et al. 2017). This has been supported by studies 
showing that impairment in insulin-degrading enzyme are associated with insulin resistance 
(Karamohamed, Demissie et al. 2003). Moreover, it has been shown that IL6 primes 
macrophages to IL4 mediated polarization towards the M2-like phenotype by inducing the 
expression of IL4R-α through STAT3-mediated activation of IL4rα promoter (Mauer, 
Chaurasia et al. 2014). Interestingly, it has also been found that some of the beneficial effect 
exercise has on metabolic health is mediated through IL6 released into circulation from 
contracting muscle, influencing metabolism in distant tissue and organs (Pedersen and 
Fischer 2007). This indicates that the role of IL6 is likely to be both context and tissue 
dependent (Mauer, Denson et al. 2015) and more research should be put into figuring out 
the characteristic of the different actions of IL6.      
 
5.4 VAT has a higher glucose uptake and are more sensitive to lipolytic stimulation. 
 
In this study we have demonstrated that both basal and insulin stimulated glucose uptake is 
higher in VAT than SAT in our cohort of obese subjects. This has also been found in other 
studies (Christen, Sheikine et al. 2010), (Westergren, Danielsson et al. 2005). The increased 
stimulated levels of glucose uptake are likely caused by elevated levels of GLUT4 expression 
in VAT relative to SAT (Westergren, Danielsson et al. 2005). Elevated basal levels of glucose 
uptake could be caused by increased expression of GLUT1, although that has not been 
confirmed. In our study, both depots showed equal sensitivity to insulin stimulation on 
glucose uptake, which has also been shown in other reports (Westergren, Danielsson et al. 
2005). We also showed that glucose levels in blood was associated with reduced glucose 
uptake, which was most prominent in SAT. However, the associations did not reach 
significance, and we found no association between insulin sensitivity on glucose uptake with 
glucose level in blood. It should be emphasized that muscle tissue are responsible for most 
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(75-80%) of total body glucose uptake, and that adipose tissue only account for a smaller 
fraction of total body glucose uptake, leading to the conclusion that investigating glucose 
uptake in adipose tissue independently not necessarily explain glucose intolerance at 
systemic level (Honka, Latva-Rasku et al. 2018). Numerous studies have reported that an 
increased tendency to store fat in VAT are more detrimental to health, and it has been 
pointed on the fact that this fat depot are drained by the portal circulation causing free fatty 
acids to reach the liver in high concentrations (Rebuffe-Scrive, Andersson et al. 1989). 
Consequently, it is reasonable to believe that an elevated lipolysis in VAT relative to SAT is 
associated with a worsened metabolic profile. We found that stimulated lipolysis is 
significantly higher in VAT than SAT of obese subjects, which is also confirmed in other 
reports, and suggests that increased VAT mass has the potential to cause a marked exposure 
of the liver to free fatty acids via the portal drainage (Rebuffe-Scrive, Andersson et al. 1989). 
It has been reported a strong association of lipolysis and insulin resistance, and the lipolytic 
response to β-adrenergic stimulation is reported to be increased in VAT and decreased in 
SAT in insulin resistant subjects (Morigny, Houssier et al. 2016). Moreover, follow-up studies 
of morbidly obese patients undergoing bariatric surgery has reported a positive association 
between reduction in lipolytic rate and improvement of insulin sensitivity (Girousse, 
Tavernier et al. 2013). In support to this, we found a strong negative association of the 
lipolytic response with insulin sensitivity in VAT. Unexpectedly, our data indicated a negative 
association of both basal and stimulated lipolytic rate with measures of insulin resistance 
(HOMA-IR), and a positive association of basal lipolysis with insulin sensitivity on glucose 
uptake in VAT. Moreover, BMI showed a non-significant negative association with lipolysis in 
bot SAT and VAT. However, it is important to emphasize that we measured lipolysis per 
volume fat mass, and did not take into account differences in distribution of fat mass 
between SAT and VAT. Considering the expanded fat volume of severely obese subjects, 
there is a much greater potential of causing harmful effects on metabolic health by ectopic 







5.4 Summary, Limitations and future perspective 
 
In summary, our data shows that macrophages are more abundant in SAT than VAT of obese 
subjects. Both flow cytometry data and gene expression analysis support an association of 
anti-inflammatory M2-like macrophages in SAT and insulin resistance and an association 
between systemic inflammation and inflammation in VAT. We should, however, be 
precautious when interpreting the correlation analysis of the flow cytometry data due to the 
limited sample size of 16 subjects. Moreover, the gene expression data are derived from 
whole tissue biopsies and thus represents the average expression level from many different 
cell types and are thereby not directly comparable with the flow cytometry data, which 
provide a more precise information of the cellular composition. Furthermore, it has been 
shown that TREM2 is also expressed by adipocytes and non-immune cells in the adipose 
tissue (Liu, Li et al. 2019). Moreover, limited access on lean healthy controls and the fact that 
one from the control group present with highest HOMA-IR, CRP levels and M1/M2 ratio limit 
the potential to perform a statistically meaningful analysis to assess whether obesity is 
associated with adipose tissue inflammation or insulin resistance. The fact that some 
patients are medically treated for T2DM to manage their glucose intolerance and insulin 
resistance brings further complexity to the analysis. In addition, the severely obese patients 
are encouraged to follow a caloric restrict diet the last weeks ahead of bariatric surgery, 
which may lead to weight loss and modulate the composition of macrophages and level of 
insulin sensitivity. Future studies should include a higher number of lean healthy controls 
and look more into how to best define different subsets of macrophages with the aim of 
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Figure 1. Gating strategy for quantification of CCR2, CD163 and CD16 expressing cells. The gating strategy for quantifying 
the fraction of Monocytes, M1- and M2-like macrophages expressing the receptors CCR2 (A), CD163 (B) and CD16 (C) from 
one representative population.  
